180 related articles for article (PubMed ID: 30295175)
1. Considerations for Preclinical Safety Assessment of Adeno-Associated Virus Gene Therapy Products.
Assaf BT; Whiteley LO
Toxicol Pathol; 2018 Dec; 46(8):1020-1027. PubMed ID: 30295175
[TBL] [Abstract][Full Text] [Related]
2. Safety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera®).
Salmon F; Grosios K; Petry H
Expert Rev Clin Pharmacol; 2014 Jan; 7(1):53-65. PubMed ID: 24308784
[TBL] [Abstract][Full Text] [Related]
3. The Adeno-associated Virus - A Safe and Promising Vehicle for Liverspecific Gene Therapy of Inherited and Non-inherited Disorders.
Mak KY; Rajapaksha IG; Angus PW; Herath CB
Curr Gene Ther; 2017; 17(1):4-16. PubMed ID: 28292253
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in various adeno-associated viruses (AAVs) as gene therapy agents in hepatocellular carcinoma.
Hadi M; Qutaiba B Allela O; Jabari M; Jasoor AM; Naderloo O; Yasamineh S; Gholizadeh O; Kalantari L
Virol J; 2024 Jan; 21(1):17. PubMed ID: 38216938
[TBL] [Abstract][Full Text] [Related]
5. Safety of adeno-associated virus gene therapy vectors: a current evaluation.
Monahan PE; Jooss K; Sands MS
Expert Opin Drug Saf; 2002 May; 1(1):79-91. PubMed ID: 12904163
[TBL] [Abstract][Full Text] [Related]
6. Retinal gene delivery by adeno-associated virus (AAV) vectors: Strategies and applications.
Schön C; Biel M; Michalakis S
Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):343-52. PubMed ID: 25615882
[TBL] [Abstract][Full Text] [Related]
7. Systemic delivery of adeno-associated viral vectors.
Duan D
Curr Opin Virol; 2016 Dec; 21():16-25. PubMed ID: 27459604
[TBL] [Abstract][Full Text] [Related]
8. Adeno-associated virus vectors: potential applications for cancer gene therapy.
Li C; Bowles DE; van Dyke T; Samulski RJ
Cancer Gene Ther; 2005 Dec; 12(12):913-25. PubMed ID: 15962012
[TBL] [Abstract][Full Text] [Related]
9. Gene therapy using adeno-associated virus vectors.
Daya S; Berns KI
Clin Microbiol Rev; 2008 Oct; 21(4):583-93. PubMed ID: 18854481
[TBL] [Abstract][Full Text] [Related]
10. Strategies to circumvent humoral immunity to adeno-associated viral vectors.
Tse LV; Moller-Tank S; Asokan A
Expert Opin Biol Ther; 2015 Jun; 15(6):845-55. PubMed ID: 25985812
[TBL] [Abstract][Full Text] [Related]
11. Adeno-associated virus vectors and neurological gene therapy.
Ojala DS; Amara DP; Schaffer DV
Neuroscientist; 2015 Feb; 21(1):84-98. PubMed ID: 24557878
[TBL] [Abstract][Full Text] [Related]
12. Preclinical gene therapy studies for hemophilia using adeno-associated virus (AAV) vectors.
Couto LB
Semin Thromb Hemost; 2004 Apr; 30(2):161-71. PubMed ID: 15118928
[TBL] [Abstract][Full Text] [Related]
13. Adeno-Associated Virus Gene Therapy: Translational Progress and Future Prospects in the Treatment of Heart Failure.
Bass-Stringer S; Bernardo BC; May CN; Thomas CJ; Weeks KL; McMullen JR
Heart Lung Circ; 2018 Nov; 27(11):1285-1300. PubMed ID: 29703647
[TBL] [Abstract][Full Text] [Related]
14. Adeno-Associated Virus Vector for Central Nervous System Gene Therapy.
Zhu D; Schieferecke AJ; Lopez PA; Schaffer DV
Trends Mol Med; 2021 Jun; 27(6):524-537. PubMed ID: 33895085
[TBL] [Abstract][Full Text] [Related]
15. Identification and Validation of Small Molecules That Enhance Recombinant Adeno-associated Virus Transduction following High-Throughput Screens.
Nicolson SC; Li C; Hirsch ML; Setola V; Samulski RJ
J Virol; 2016 Aug; 90(16):7019-7031. PubMed ID: 27147738
[TBL] [Abstract][Full Text] [Related]
16. Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors.
Shi W; Arnold GS; Bartlett JS
Hum Gene Ther; 2001 Sep; 12(14):1697-711. PubMed ID: 11560765
[TBL] [Abstract][Full Text] [Related]
17. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ
Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787
[TBL] [Abstract][Full Text] [Related]
18. Adeno-Associated Virus (AAV) as a Vector for Gene Therapy.
Naso MF; Tomkowicz B; Perry WL; Strohl WR
BioDrugs; 2017 Aug; 31(4):317-334. PubMed ID: 28669112
[TBL] [Abstract][Full Text] [Related]
19. Humoral immunity to AAV vectors in gene therapy: challenges and potential solutions.
Masat E; Pavani G; Mingozzi F
Discov Med; 2013 Jun; 15(85):379-89. PubMed ID: 23819952
[TBL] [Abstract][Full Text] [Related]
20. [Adeno-associated viral vectors: methods for production and purification for gene therapy applications].
Mena-Enriquez M; Flores-Contreras L; Armendáriz-Borunda J
Rev Invest Clin; 2012; 64(5):487-94. PubMed ID: 23544311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
